Longitudinal Study of Optic Disk Perfusion and Retinal Structure in Leber's Hereditary Optic Neuropathy.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
03 01 2022
Historique:
entrez: 31 1 2022
pubmed: 1 2 2022
medline: 19 2 2022
Statut: ppublish

Résumé

The purpose of this study was to evaluate optic disk perfusion and neural retinal structure in patients with subacute Leber's hereditary optic neuropathy (LHON) and LHON carriers, as compared with healthy controls. This study included 8 patients with LHON in the subacute stage, 10 asymptomatic carriers of a LHON-associated mitochondrial DNA mutation, and 40 controls. All subjects underwent measurement of the retinal nerve fiber layer (RNFL) thickness, the ganglion cell-inner plexiform layer (GCIPL) thickness using optical coherence tomography and optic disk microvascular perfusion (Mean Tissue [MT]) using laser speckle flowgraphy (LSFG). Patients were re-examined after a median interval of 3 months from the baseline visit. LHON carriers had higher values of RNFL thickness, GCIPL thickness, and disk area than controls (P < 0.05), whereas MT was not different between the two groups (P = 0.936). Median MT and RNFL thickness were 32% and 15% higher in the early subacute stage of the disease than in controls (P < 0.001 and P = 0.001). MT declined below the values of controls during the late subacute stage (P = 0.024), whereas RNFL thickness declined later during the dynamic stage (P < 0.001). GCIPL thickness was lower in patients with LHON than in controls independently of the stage of the disease (P < 0.001). The high blood flow at the optic disk during the early subacute stage may be the consequence of vasodilation due to nitric oxide release as compensation to mitochondrial impairment. Optic disk perfusion as measured by LSFG is a promising biomarker for LHON diagnosis and monitoring as well as an objective outcome measure for assessing response to therapies.

Identifiants

pubmed: 35098304
pii: 2778322
doi: 10.1167/iovs.63.1.43
pmc: PMC8802032
doi:

Substances chimiques

DNA, Mitochondrial 0
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

43

Références

Microvasc Res. 2011 Nov;82(3):351-5
pubmed: 21771603
Clin Exp Ophthalmol. 2018 Dec;46(9):1055-1062
pubmed: 29790285
Medicine (Baltimore). 2015 Feb;94(6):e519
pubmed: 25674750
JAMA Ophthalmol. 2020 Jan 1;138(1):86-94
pubmed: 31774456
Neuroophthalmology. 2018 Oct 11;43(6):411-416
pubmed: 32165903
Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1666-74
pubmed: 19098324
Sci Rep. 2021 Mar 25;11(1):6847
pubmed: 33767305
Neuropathology. 2019 Oct;39(5):404-410
pubmed: 31408922
Biochim Biophys Acta. 2009 May;1787(5):518-28
pubmed: 19268652
Ophthalmology. 2017 Jun;124(6):843-850
pubmed: 28196731
Acta Ophthalmol. 2021 May;99(3):e445-e446
pubmed: 32701205
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1126-41
pubmed: 16505051
Invest Ophthalmol Vis Sci. 2014 Nov 06;55(12):7991-6
pubmed: 25377226
Acta Ophthalmol. 2019 Feb;97(1):e71-e76
pubmed: 30259673
Ophthalmology. 2010 Mar;117(3):623-7
pubmed: 20031228
Brain. 2004 Oct;127(Pt 10):2183-92
pubmed: 15342361
Transl Vis Sci Technol. 2021 Jan 07;10(1):13
pubmed: 33510952
Prog Retin Eye Res. 2011 Mar;30(2):81-114
pubmed: 21112411
JAMA Ophthalmol. 2016 Nov 1;134(11):1332-1334
pubmed: 27711925
Ophthalmic Res. 2021;64(5):863-870
pubmed: 34247170
Curr Eye Res. 2020 Nov;45(11):1438-1442
pubmed: 32255706
Invest Ophthalmol Vis Sci. 2012 Nov 09;53(12):7608-17
pubmed: 23060142
Acta Ophthalmol. 2022 Feb;100(1):e181-e191
pubmed: 33880888
Cell Death Dis. 2015 Dec 17;6:e2021
pubmed: 26673666
Arch Ophthalmol. 1982 Oct;100(10):1597-602
pubmed: 7138328
Sci Rep. 2016 Nov 17;6:37332
pubmed: 27853297
Prog Retin Eye Res. 2004 Jan;23(1):53-89
pubmed: 14766317
Arch Ophthalmol. 1984 Jul;102(7):981-9
pubmed: 6743093
PLoS One. 2018 Nov 29;13(11):e0208145
pubmed: 30496251
Acta Ophthalmol. 2017 Jun;95(4):e344-e345
pubmed: 27778481
Transl Vis Sci Technol. 2020 Apr 16;9(5):9
pubmed: 32821481
Arch Ophthalmol. 1983 Jul;101(7):1059-68
pubmed: 6870629
PLoS One. 2017 Sep 12;12(9):e0184772
pubmed: 28898284
Asia Pac J Ophthalmol (Phila). 2016 Mar-Apr;5(2):151-8
pubmed: 26649761
Invest Ophthalmol Vis Sci. 2012 Dec 17;53(13):8303-9
pubmed: 23169886
Br J Ophthalmol. 2016 Sep;100(9):1232-7
pubmed: 26614631
Br J Ophthalmol. 2018 Dec;102(12):1679-1683
pubmed: 29472236

Auteurs

Giacomo Calzetti (G)

Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
Department of Ophthalmology, University of Basel, Basel, Switzerland.
Department of Ophthalmology, University Hospital of Parma, Parma, Italy.

Chiara La Morgia (C)

IRCCS, Istituto delle Scienze Neurologiche di Bologna, Ospedale Bellaria, Bologna, Italy.

Marco Cattaneo (M)

Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
Department of Clinical Research, University of Basel, Basel, Switzerland.

Arturo Carta (A)

Department of Ophthalmology, University Hospital of Parma, Parma, Italy.

Francesca Bosello (F)

Department of Neurosciences, Biomedicine and Movement Sciences, Eye Clinic, Ocular Immunology and Neuroophthalmology Service, AOUI-University of Verona, Verona, Italy.

Giulia Amore (G)

Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Michele Carbonelli (M)

Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Maria Lucia Cascavilla (ML)

Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy.

Stefano Gandolfi (S)

Department of Ophthalmology, University Hospital of Parma, Parma, Italy.

Valerio Carelli (V)

IRCCS, Istituto delle Scienze Neurologiche di Bologna, Ospedale Bellaria, Bologna, Italy.
Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Leopold Schmetterer (L)

Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.

Hendrik P N Scholl (HPN)

Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
Department of Ophthalmology, University of Basel, Basel, Switzerland.

Piero Barboni (P)

Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy.
Studio Oculistico d'Azeglio, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH